Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...
Neurocrine price target raised to $176 from $162 at UBS
UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...
Neurocrine Biosciences director sells shares worth $21.8 million
Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold 146,105 ...
DelveInsight Business Research, LLP: Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight
Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective ...
XBI: Diverse Holding Amid Strong Catalysts, Buy
Invest in SPDR S&P Biotech ETF (XBI) for long-term growth potential and diverse, equal-weighted portfolio in the biotech ...
Le Lézard7h
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the ...